Laboratory for Molecular Medicine (LMM)

The Laboratory for Molecular Medicine (LMM) is a CLIA-certified molecular diagnostic laboratory, operated by Partners HealthCare Personalized Medicine and led by a group of Harvard Medical School-affiliated faculty. The LMM was the first laboratory to offer a clinically available test for hypertrophic cardiomyopathy (HCM). Since the initial launch in 2007, sequencing-based testing has expanded to become more comprehensive and include additional forms of cardiomyopathy. To date, over 6,000 tests have been performed. Patients can choose from several testing options, including a HCM-focused gene panel for individuals and families with a clear diagnosis of HCM, a comprehensive multi-cardiomyopathy panel for individuals where the clinical presentation is more complex, and whole exome and whole genome sequencing. In addition, known mutation testing is available for individuals who wish to know whether they carry a predisposing cardiomyopathy variant that was previously identified in their family. Regardless of which test is performed, variants identified by the LMM undergo a rigorous assessment to determine their significance. After a decade of cardiomyopathy testing, the LMM has established itself as a leader in this field and is spearheading large national and international efforts to help centralize and share cardiomyopathy variants, standardize their interpretation, and provide guidance on which genes are supported by a sufficient amount of scientific evidence to warrant inclusion in disease-focused gene panels ( As a result of these efforts, as well as its tight integration with leading clinical and scientific experts at Harvard Medical School, the LMM is able to apply its deep knowledge to create test reports with detailed variant-level summaries of current knowledge as well as individualized summaries that interpret genetic findings in the context of each individual's clinical features and family history. For more information see LMM